Next Article in Journal
Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
Next Article in Special Issue
TRPV3 in Drug Development
Previous Article in Journal
1H and 15N NMR Analyses on Heparin, Heparan Sulfates and Related Monosaccharides Concerning the Chemical Exchange Regime of the N-Sulfo-Glucosamine Sulfamate Proton
Previous Article in Special Issue
TRPV1: A Target for Rational Drug Design

Targeting TRPM2 in ROS-Coupled Diseases

Division of Pharmacology, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo 164-8530, Japan
Author to whom correspondence should be addressed.
Academic Editors: Arpad Szallasi and Susan M. Huang
Pharmaceuticals 2016, 9(3), 57;
Received: 23 May 2016 / Revised: 5 August 2016 / Accepted: 5 September 2016 / Published: 7 September 2016
Under pathological conditions such as inflammation and ischemia-reperfusion injury large amounts of reactive oxygen species (ROS) are generated which, in return, contribute to the development and exacerbation of disease. The second member of the transient receptor potential (TRP) melastatin subfamily, TRPM2, is a Ca2+-permeable non-selective cation channel, activated by ROS in an ADP-ribose mediated fashion. In other words, TRPM2 functions as a transducer that converts oxidative stress into Ca2+ signaling. There is good evidence that TRPM2 plays an important role in ROS-coupled diseases. For example, in monocytes the influx of Ca2+ through TRPM2 activated by ROS contributes to the aggravation of inflammation via chemokine production. In this review, the focus is on TRPM2 as a molecular linker between ROS and Ca2+ signaling in ROS-coupled diseases. View Full-Text
Keywords: TRPM2; Ca2+ signaling; reactive oxygen species; ROS-coupled diseases TRPM2; Ca2+ signaling; reactive oxygen species; ROS-coupled diseases
Show Figures

Figure 1

MDPI and ACS Style

Yamamoto, S.; Shimizu, S. Targeting TRPM2 in ROS-Coupled Diseases. Pharmaceuticals 2016, 9, 57.

AMA Style

Yamamoto S, Shimizu S. Targeting TRPM2 in ROS-Coupled Diseases. Pharmaceuticals. 2016; 9(3):57.

Chicago/Turabian Style

Yamamoto, Shinichiro, and Shunichi Shimizu. 2016. "Targeting TRPM2 in ROS-Coupled Diseases" Pharmaceuticals 9, no. 3: 57.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop